Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. - Wikidata - awgldk - TriplyDB

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37929798

about

Aldose reductase from Schistosoma japonicum: crystallization and structure-based inhibitor screening for discovering antischistosomal lead compounds Pixantrone: merging safety with efficacy.

P2860

Q27678492-E1FCEAC7-37EA-49D4-8EBD-17399B7E479B Q38078425-799B6B55-D5CC-4F09-B0DC-E442FE153302

P2860

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37929798

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

@en

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

@nl

type

label

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

@en

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

@nl

prefLabel

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

@en

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

@nl

P1433

Q37929798-F9DAC3B8-EF1D-4712-BA8B-8A3880F53274

P1476

Q37929798-2A205F23-E01E-47EC-8513-366FA67016DB

P2093

Q37929798-55BF1E66-E6DF-4666-A61C-E4C74E8C670B

Q37929798-5BA4429A-07B0-4F2E-BA2E-1F6ECB0A1D10

P2860

Q37929798-012AE7A5-C3C2-4E66-BF2C-B987B9EC3D90

Q37929798-0939C7D2-3A2F-4A81-92D8-6083B7BB729B

Q37929798-0F488FFC-DA36-4B6A-B318-4E857D7ABDC9

Q37929798-21877DB7-43C5-413C-B45B-E34D752884E7

Q37929798-3414AF03-6177-43B3-A913-B795ABAFEC16

Q37929798-3E3808EC-FFEA-4769-83E6-76AB6914EA11

Q37929798-42727224-495E-4D06-9839-F89C3B0E660B

Q37929798-4327C234-83AF-4606-8F36-4C7CACF31A84

Q37929798-4799A5B2-947F-4B01-AF06-1113D7BA7E76

Q37929798-4A468E0D-4765-4B3C-9163-561366529FBD

P304

Q37929798-58E56740-7D86-40EB-BB6E-26F561D93CE8

P31

Q37929798-4C972AB5-4918-4344-84FE-0C52664371A6

P356

Q37929798-12E24C5A-59C7-475B-AECD-6F67085E7B64

P407

Q37929798-0FD51382-DFF0-4F74-A77B-99E1D7D01A23

P433

Q37929798-112D299C-A460-4741-8708-8A6949193F75

P478

Q37929798-46F4D0B4-AB68-4D4E-9E85-B6CC1CE5D548

P577

Q37929798-2D317652-295B-4F08-99AB-1D4B663E5B99

P698

Q37929798-2AC93DBE-E919-4B57-8FB5-8729C72AEA9D

P356

17425255.2011.618834

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.

@en

P2093

Mariam Jamal-Hanjani

http://www.w3.org/2001/XMLSchema#string

Ruth Pettengell

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent

CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.

P304

1441-1448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2011.618834

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21905966

http://www.w3.org/2001/XMLSchema#string